Welcome to the website of Dr. Abbas Salihi, a well-known cancer biology researcher. In 2012, I received my PhD from Zakho University in collaboration with the Institute of Biophysics (IBF), National Research Council (CNR) in Genoa, Italy. Later, in 2022, I was going to continue my postdoctoral study at the Karolinska Institutet in Stockholm, Sweden. 

The role of gasotransmitters, especially nitric oxide and hydrogen sulfide, in carcinogenesis and cancer progression is my field of research interest. The interactions between these gases, the gene mutations that produce them, and the characteristics of enzyme expression in various cancer types are the main focus of my studies. "NOS3 and CTH gene mutations as new molecular markers for detection of lung adenocarcinoma" and "Gasotransmitters in the tumour microenvironment: Impacts on cancer chemotherapy" articles demonstrate our commitment to understanding the molecular complexity of cancer biology.

The study's methodology focuses on the understanding of the molecular mechanisms underlying cancer, particularly angiogenesis. We aim to uncover the complex details of gasotransmitter involvement in the growth of cancer using a comprehensive range of molecular techniques such as conventional PCR, real-time PCR, Western blotting, Sanger sequencing, and next-generation sequencing. Statistical analysis is an important part of our job, and I have over 15 years of expertise with statistical software like SPSS and GraphPad Prism, providing critical insights for data interpretation.

In terms of therapeutic significance, my research group mainly examines human cancer samples, enabling us to directly link our results with the complicated nature of human cancer biology. Furthermore, our research extends beyond clinical samples to include animal models, cell lines, and other human samples. This comprehensive strategy allows us to get a thorough knowledge of the roles that nitric oxide and hydrogen sulfide play in cancer at the beginning and progression, providing critical information for the development of innovative therapies.